Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00324506 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT00324506 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 43 participants.
The verdict
NCT00324506, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The primary objective of this safety/mechanistic study is to determine the safety and tolerability of oral Cellcept when compared with weekly intramuscular Avonex in relapsing multiple sclerosis. Safety will be assessed by virtue of changes in size and number of lesions on MRI scans.
Interventions
- DRUG Mycophenolate Mofetil (CellCept)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00324506
The ClinicalTrials.gov registry entry for NCT00324506 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mycophenolate Mofetil (CellCept) is the first listed.
NCT00324506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00324506 about?
NCT00324506 is a clinical study titled "Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis". The primary objective of this safety/mechanistic study is to determine the safety and tolerability of oral Cellcept when compared with weekly intramuscular Avonex in relapsing multiple sclerosis. Safety will be assessed by virtue of changes in size and number of lesions on MRI scans.
What is the current status of trial NCT00324506?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2006-05. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00324506?
The interventions under investigation include: Mycophenolate Mofetil (CellCept) (DRUG).
Who is sponsoring clinical trial NCT00324506?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.